Novo Nordisk A/S (NVO) — closed signal from September 14, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 13, 2025.
Predicted vs. what happened
What happened
Reached 76% of the predicted growth at its peak, without hitting the target.
The thesis — published September 14, 2025
Novo Nordisk looks like a reasonable buy on a dip. Its diabetes and weight-loss drugs lead the market, and the price trend is improving without having run too far. The plan to reorganize 9,000 jobs signals tighter focus, which can help profits. Over the next three months, steady demand and solid execution could support a gradual rise, with pullbacks likely to be smaller and easier to sit through.
Primary drivers
- Leader in diabetes/weight drugs; demand remains strong and keeps building.
- Trend looks better, with lots more people buying than usual recently.
- Cutting 9,000 roles aims to streamline operations and lift profitability.
- Healthcare name with steady need that can grow even in slow economies.
How it played out
NVO: target missed after an early peak
Lyra published NVO at 54.87 on 2025-09-14 with an 18% expected rise and a 64.75 target. The thesis pointed to leadership in diabetes and weight-loss drugs, strong demand, an improving price trend, the planned 9,000-role reorganization, and steady healthcare demand.
Inside the window, NVO rose to 62.32 on 2025-09-19, a 13.6% peak gain. That was below the 64.75 target. It never got there. By 2025-12-13, the stock ended at 50.18. The thesis partly played out early, then missed by the end of the window.
What happened during the window
On 2025-11-05, Novo Nordisk reported third-quarter sales of 75 billion Danish kroner and cut its full-year growth outlook. In late October, Novo Nordisk made a bid for Metsera, which was still being contested in early November.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.